BONE DISEASE

por Terpos, E.
Publicado 2023

ANTIBODY DRUG CONJUGATES (ADCS)

por Terpos, E.
Publicado 2023

COVID-19 AND MYELOMA

por Ludwig, H, Sonneveld, P, Boccadoro, M, Terpos, E
Publicado 2022

Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis

por Kostopoulos, I V, Paterakis, G, Pavlidis, D, Kastritis, E, Terpos, E, Tsitsilonis, O E, Papadhimitriou, S I
Publicado 2017

Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging

por Kastritis, E, Gavriatopoulou, M, Dimopoulos, M A, Eleutherakis-Papaiakovou, E, Kanellias, N, Roussou, M, Pamboucas, C, Toumanidis, S T, Terpos, E
Publicado 2015

Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma

por Spanoudakis, E, Papoutselis, M, Terpos, E, Dimopoulos, M A, Tsatalas, C, Margaritis, D, Rahemtulla, A, Kotsianidis, I, Karadimitris, A
Publicado 2016

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

por Raje, N, Vadhan-Raj, S, Willenbacher, W, Terpos, E, Hungria, V, Spencer, A, Alexeeva, Y, Facon, T, Stewart, A K, Feng, A, Braun, A, Balakumaran, A, Roodman, G D
Publicado 2016

Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment

por Terpos, E, Migkou, M, Christoulas, D, Gavriatopoulou, M, Eleutherakis-Papaiakovou, E, Kanellias, N, Iakovaki, M, Panagiotidis, I, Ziogas, D C, Fotiou, D, Kastritis, E, Dimopoulos, M A
Publicado 2016

B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA

por Terpos, E, Gavriatopoulou, M, Ntanasis-Stathopoulos, I, Briasoulis, A, Gumeni, S, Malandrakis, P, Papanagnou, E-D, Migkou, M, Kanellias, N, Kastritis, E, Trougakos, I P, Dimopoulos, M A
Publicado 2022

P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY

por Spiliopoulou, V., Ntanasis-Stathopoulos, I., Malandrakis, P., Gavriatopoulou, M., Theodorakakou, F., Fotiou, D., Syrigou, R. E., Migkou, M., Roussou, M., Eleutherakis-Papaiakovou, E., Kastritis, E., Dimopoulos, M. A, Terpos, E.
Publicado 2023

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA

por Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Eleutherakis-Papaiakovou, E., Malandrakis, P., Spiliopoulou, V., Syrigou, R.E., Theodorakakou, F., Fotiou, D., Migkou, M., Roussou, M., Kastritis, E., Dimopoulos, M.A., Terpos, E.
Publicado 2023

P1507: CLINICAL PROFILE OF COVID-19 INFECTION AND IMMUNE RESPONSE AFTER 3AND6 MONTH VACCINATION AGAINST SARS-COV-2 IN ADULT PATIENTS WITH TRANSFUSION-DEPENDENT THALASSAEMIA-THE EXP...

por Delaporta, P., Terpos, E., Solomou, E. E., Gumeni, S., Chatzielefteriou, M.-I., Toutoudaki, K., Kyriakopoulou, D., Ioakeimidou, N., Ntanasis-Stathopoulos, I., Papassotiriou, I., Trougakos, I. P., Dimopoulos, M. A., Kattamis, A.
Publicado 2022

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2

por Gavalas, N G, Tsiatas, M, Tsitsilonis, O, Politi, E, Ioannou, K, Ziogas, A C, Rodolakis, A, Vlahos, G, Thomakos, N, Haidopoulos, D, Terpos, E, Antsaklis, A, Dimopoulos, M A, Bamias, A
Publicado 2012

P22: A NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IXAZOMIB IN REAL-WORLD SETTINGS IN GREECE; INTERIM RESULTS...

por Katodritou, E, Kyrtsonis, MC, Delimpasi, S, Spanoudakis, E, Vassilopoulos, G, Zikos, P, Viniou, N, Kaiafa, G, Papathanasiou, M, Pappa, V, Michalis, E, Adamopoulos, I, Kokoviadou, K, Tsirakis, G, Poziopoulos, C, Terpos, E
Publicado 2022

P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

por Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Malandrakis, P., Fotiou, D., Kanellias, N., Migkou, M., Theodorakakou, F., Spiliopoulou, V., Syrigou, R., Eleutherakis-Papaiakovou, E., Gkolfinopoulos, S., Manousou, K., Kastritis, E., Dimopoulos, M.A., Terpos, E.
Publicado 2023

High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomat...

por Terpos, E, Christoulas, D, Kastritis, E, Bagratuni, T, Gavriatopoulou, M, Roussou, M, Papatheodorou, A, Eleutherakis-Papaiakovou, E, Kanellias, N, Liakou, C, Panagiotidis, I, Migkou, M, Kokkoris, P, Moulopoulos, L A, Dimopoulos, M A
Publicado 2016

P16: DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY

por Terpos, E, Ntanasis-Stathopoulos, I, Kastritis, E, Hatjiharissi, E, Katodritou, E, Eleutherakis-Papaiakovou, E, Verrou, E, Gavriatopoulou, M, Leonidakis, A, Delimpasi, S, Malandrakis, P, Kyrtsonis, M-C, Papaioannou, M, Symeonidis, A, Dimopoulos, MA
Publicado 2022

Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit

por Dimopoulos, M A, Roussou, M, Gavriatopoulou, M, Fotiou, D, Ziogas, D C, Migkou, M, Panagiotidis, I, Eleutherakis-Papaiakovou, E, Kanellias, N, Psimenou, E, Marinaki, S, Bacharaki, D, Mparmparoussi, D, Matsouka, C, Giannouli, S, Terpos, E, Kastritis, E
Publicado 2017

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

por Terpos, E., Branagan, A.R., García-Sanz, R., Trotman, J., Greenberger, L.M., Stephens, D.M., Morel, P., Kimby, E., Frustaci, A.M., Hatjiharissi, E., San-Miguel, J., Dimopoulos, M.A., Treon, S.P., Leblond, V.
Publicado 2023

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

por Caers, J., Paiva, B., Zamagni, E., Leleu, X., Bladé, J., Kristinsson, S. Y., Touzeau, C., Abildgaard, N., Terpos, E., Heusschen, R., Ocio, E., Delforge, M., Sezer, O., Beksac, M., Ludwig, H., Merlini, G., Moreau, P., Zweegman, S., Engelhardt, M., Rosiñol, L.
Publicado 2018